Back to results
US 11,446,314 B2Granted
Immunoablative therapies
AssigneeAVM Biotechnology, LLC
InventorTheresa Deisher
Life of this patent
Estimating the term…
Abstract
This invention pertains to pharmaceutical compositions comprising a glucocorticoid for use in the treatment of diseases by immunoablation. The compositions of the invention may be for use in the treatment of diseases that are mediated by immune cells such as lymphocytes.
Claims14
A method of treating a lymphocyte mediated disease in a subject, comprising administering a pharmaceutical composition comprising dexamethasone or betamethasone and one or more pharmaceutically acceptable carriers, preservatives, and/or chelating agents, to the subject at a dose of about 9 to about 26 mg/kg human equivalent dose (HED) of dexamethasone base,
- wherein administering the pharmaceutical composition depletes splenic, peripheral blood, thymic and bone marrow lymphocytes in the subject by at least 50%;
- wherein the method does not comprise co-administration of a chemotherapy agent;
- and
- wherein the lymphocyte mediated disease is not graft versus host disease (GVHD).
1 more element
Dependencies are inferred from the claim text.